Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00410748|
Recruitment Status : Completed
First Posted : December 13, 2006
Last Update Posted : April 27, 2010
|Condition or disease||Intervention/treatment||Phase|
|Pain Analgesics, Opioid||Drug: OROS hydromorphone HCI CR||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||388 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Tolerability of Long-term Administration of Dilaudid CR (Hydromorphone HCI)|
|Study Completion Date :||June 2000|
- Effectiveness of OROS hydromorphone was maintained throughout the study. OROS hydromorphone provided moderate pain relief in patients with chronic cancer/chronic non-malignant pain.
- Long term administration of OROS hydromorphone was safe and well tolerated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410748
|Study Director:||Alza Corporation Clinical Trial||ALZA|